FacebookTwitterGoogle+RedditEmail

Molecule of the Year: Cannabiodiol

by FRED GARDNER

THC -delta-9 tetrahydrocannabinol- is not the only active ingredient in cannabis. At least five other cannabinoids exhibit biological activity, and so do some terpenes and flavonoids. All these compounds are found in the resin stored in the plant’s glandular trichomes. They are chemically related.

THC predominates in plants bred for psychoactivity (as cannabis plants have been bred for generations in California and elsewhere). Cannabidiol -CBD- is the predominant cannabinoid in plants typically bred for fiber. There are only trace quantities of CBD in high-THC plants because one form of the same gene codes for THC synthase and the other codes for CBD synthase. Thus growers selecting for high THC content get low CBD.

California growers hoping to develop plants with a high CBD-to-THC ratio have been stymied by lack of access to an analytical test lab. In surreptitious tests, “high grade” buds were reportedly in the range of 15-20% THC and 0.1% CBD.

The U.S. Drug Enforcement Administration has placed CBD on Schedule I even though CBD has no known adverse effects and doesn’t induce “euphoria.” The most dire effects attributed to marijuana -tachycardia (accelerated heartbeat), panic, confusion, anxiety, even psychosis- are effects of THC that CBD has been shown to mitigate!

By listing CBD as a Schedule 1 substance and denying growers the means to develop high-CBD plant strains, the government is protecting the American people from an immunomodulator with anti-inflammatory, anti-convulsant, anti-psychotic, anti-oxidant, and neuro-protective properties. In whose interests could that possibly be?

BF Mechoulam on CBD END BF

The chemist who worked out the precise structure of CBD 45 years ago, Raphael Mechoulam, gave a “review talk” at this year’s meeting of the International Association for Cannabis as Medicine. Mechoulam had just gotten his PhD in chemistry in the Fall of ’62 and was looking for a research project that might lead to tenure at the Weizmann Institute. He chose to analyze the components of cannabis, he said, thinking “it’s a minor project, it will be finished off in six months.”

Hashish of Lebanese origin was obtained from the police -“There is a fantastic collaboration between Arabs and Jews in smuggling,” Mechoulam observed- and a dozen constituents were then identified by two types of chromatography. (Some cannabis constituents had been identified previously, including CBD, which Roger Adams of the University of Illinois isolated in the early 1940s.)

It was generally assumed throughout the ’60s and ’70s that the cannabinoids exerted effects not by binding to a specific receptor but “nonspecifically” by altering the lipid structure of cellular membranes. Mechoulam established that the action was specific by purifying THC and showing that only the natural version of the molecule -and not its synthetic mirror image- was exerting the effect. In 1988 Alynn Howlett found that THC was indeed activating a receptor. It was dubbed “CB1” and was found in those areas of the brain involved in movement, stress, cognitive function – “everywhere it would be expected,” said Mechoulam, given what was known about the effects of cannabis on people.

Unlike THC, CBD hardly binds to the CB1 receptor. It binds to a second cannabinoid receptor -CB2-originally found in spleen cells by S. Munro of Cambridge University in 1993 and subsequently found in the stomach, liver, heart, kidney, lymph and immune cells, bones, endocrine glands, and throughout the peripheral nervous system.

In his IACM talk Mechoulam reviewed research in recent years that has shed light on aspects of CBD’s mechanism of action. Its lipid-solubility enables it to get into places in the brain that conventional neurotransmitters cannot reach. It is a potent anti-oxidative agent. It turns out to be an antagonist to a recently discovered receptor called GPR-55 to which THC and 2-AG bind as agonists. It blocks the uptake of adenosine, an inhibitory neurotransmitter that may promote sleep. It blocks the formation of various cytokines (signaling compounds not released by nerves or glands) under certain circumstances. It activates the serotonin receptors. No wonder, then, that CBD plays a role in many clinical conditions.

Conditions treatable by CBD

Mechoulam described an experiment led by Paul Consroe and colleagues in Brazil in which CBD was tested as a treatment for intractable epilepsy. Patients stayed on the anticonvulsants they had been on (which hadn’t eliminated their seizures) and added 200mg/day of CBD or a placebo. Of the seven patients getting CBD over the course of several months, only one showed no improvement; three became seizure-free; one experienced only one or two seizures, Mechoulam recalled; and two experienced reduced severity and occurrence of seizures.

“So it seemed a very promising approach,” said Mechoulam, “but unfortunately, nothing has been done ever since. To the best of my knowledge, nobody has done any work on cannabidiol in the clinic on epilepsy, and I wonder why.”

A colleague of Mechoulam’s, Marc Feldman at Imperial College, London, tested CBD on mice who had a version of rheumatoid arthritis and found that it reduced inflammation by almost 50% at the right dose -5mg/kg of body weight. But this “beautiful antiinflammatory reaction was lost if we went up to, say, 25 mg/kg,” Mechoulam said. Drug developers must bear in mind and cope with the fact that cannabinoids have a finite “therapeutic window” -they are ineffective at low and high doses.

Mechoulam has been testing CBD on mice bred to have a version of type-1 diabetes that manifests around age 14 weeks. He and his co-workers treated these mice with CBD for their first 6-7 weeks of life, then tested them 6-7 weeks later and found that only 30% had developed diabetes (compared to 90-100% given placebo).

In a follow-up experiment the mice weren’t given a course of CBD until age 14 weeks, when they were developing diabetes. They were then tested at age 24 weeks, and again only 30% of the treated mice were found to have diabetes. In other words, CBD did not just prevent onset but blocked development of diabetes.

Examination of the insulin-producing islets showed that only 8% were intact in the untreated diabetic mice, whereas 77% were intact in the mice treated with CBD. “I believe that here we have something very promising,” Mechoulam said. “We plan to have a clinical trial starting next week treating patients, and hopefully at the next meeting I will tell you that all of them are cured.”

Cardiologists working with mice at Hebrew University have found that CBD treatment at the time of a heart attack can reduce infarct size by about 66%. “So now they’re pushing me, ‘let’s have more CBD,'” Mechoulam said. “We should try it with humans in a few years.”

He went on: “What about sleep? I’m jumping from thing to thing to show you that CBD does quite a lot of things and I’m not sure that all of them are according to the same mechanism.” Mechoulam was part of a group led by Eric Murillo-Rodriguez that administered CBD to rats and determined that while THC caused sleepiness, CBD increased wakefulness and significantly decreased REM sleep. According to Mechoulam, “When one says ‘cannabis causes sleep,’ one should think really of two compounds, one that causes sleep and one that causes awakening.”

The anti-nausea and memory extinction effects of CBD “seem to be closely related,” Mechoulam said. He described the problem of anticipatory nausea, for which no good drugs are available. (The effects of chemotherapy can be so nauseating that patients start vomiting when they see the doctor or nurse who is going to administer the treatment.) Linda Parker at the University of Guelph conditioned shrews to start vomiting by administering lithium fluoride at a certain location. When the shrews were subsequently placed in that location they began vomiting. But if given CBD, they could be moved to the dreaded location without vomiting. “The conditioned-wretching reaction was completely abolished,” Mechoulam declared. [THC is anti-emetic, too; the advantage of CBD in this instance may be legal rather than medical.]

Mechoulam is hopeful that CBD can help tone down other kinds of conditioning. He described an experiment in which rats had a choice of two paths, one leading to cocaine, one to no reward. Rats like cocaine (and amphetamine) and will learn to choose the path leading to it. But if injected with CBD, they no longer show a preference for cocaine! Mechoulam characterized post-traumatic stress disorder, certain phobias and forms of chronic pain as “human situations which are conditioned” and might be amenable to treatment with CBD. “I know that many patients with PTSD take cannabis, self administered,” Mechoulam said. He has been trying to interest the Israeli Ministry of Health in testing CBD and THC at various ratios to treat PTSD.

FRED GARDNER will be opening for a band called Lake Street at the Rockitt Room (formerly the Last Day Saloon, Clement St. off 6th Ave.) Sunday, Nov. 25, 8 p.m. He can be reached at fred@plebesite.

 

 

Fred Gardner is the managing editor of O’Shaughnessy’s. He can be reached at fred@plebesite.com

More articles by:

CounterPunch Magazine

minimag-edit

bernie-the-sandernistas-cover-344x550

zen economics

Weekend Edition
January 20, 2017
Friday - Sunday
Paul Street
Divide and Rule: Class, Hate, and the 2016 Election
Andrew Levine
When Was America Great?
Jeffrey St. Clair
Roaming Charges: This Ain’t a Dream No More, It’s the Real Thing
Yoav Litvin
Making Israel Greater Again: Justice for Palestinians in the Age of Trump
Linda Pentz Gunter
Nuclear Fiddling While the Planet Burns
Ruth Fowler
Standing With Standing Rock: Of Pipelines and Protests
David Green
Why Trump Won: the 50 Percenters Have Spoken
Dave Lindorff
Imagining a Sanders Presidency Beginning on Jan. 20
Pete Dolack
Eight People Own as Much as Half the World
Roger Harris
Too Many People in the World: Names Named
Steve Horn
Under Tillerson, Exxon Maintained Ties with Saudi Arabia, Despite Dismal Human Rights Record
John Berger
The Nature of Mass Demonstrations
Stephen Zielinski
It’s the End of the World as We Know It
David Swanson
Six Things We Should Do Better As Everything Gets Worse
Alci Rengifo
Trump Rex: Ancient Rome’s Shadow Over the Oval Office
Brian Cloughley
What Money Can Buy: the Quiet British-Israeli Scandal
Mel Gurtov
Donald Trump’s Lies And Team Trump’s Headaches
Kent Paterson
Mexico’s Great Winter of Discontent
Norman Solomon
Trump, the Democrats and the Logan Act
David Macaray
Attention, Feminists
Yves Engler
Demanding More From Our Media
James A Haught
Religious Madness in Ulster
Dean Baker
The Economics of the Affordable Care Act
Patrick Bond
Tripping Up Trumpism Through Global Boycott Divestment Sanctions
Robert Fisk
How a Trump Presidency Could Have Been Avoided
Robert Fantina
Trump: What Changes and What Remains the Same
David Rosen
Globalization vs. Empire: Can Trump Contain the Growing Split?
Elliot Sperber
Dystopia
Dan Bacher
New CA Carbon Trading Legislation Answers Big Oil’s Call to Continue Business As Usual
Wayne Clark
A Reset Button for Political America
Chris Welzenbach
“The Death Ship:” An Allegory for Today’s World
Uri Avnery
Being There
Peter Lee
The Deep State and the Sex Tape: Martin Luther King, J. Edgar Hoover, and Thurgood Marshall
Patrick Hiller
Guns Against Grizzlies at Schools or Peace Education as Resistance?
Randy Shields
The Devil’s Real Estate Dictionary
Ron Jacobs
Singing the Body Electric Across Time
Ann Garrison
Fifty-five Years After Lumumba’s Assassination, Congolese See No Relief
Christopher Brauchli
Swing Low Alabama
Dr. Juan Gómez-Quiñones
La Realidad: the Realities of Anti-Mexicanism
Jon Hochschartner
The Five Least Animal-Friendly Senate Democrats
Pauline Murphy
Fighting Fascism: the Irish at the Battle of Cordoba
Susan Block
#GoBonobos in 2017: Happy Year of the Cock!
Louis Proyect
Is Our Future That of “Sense8” or “Mr. Robot”?
Charles R. Larson
Review: Robert Coover’s “Huck out West”
David Yearsley
Manchester-by-the-Sea and the Present Catastrophe
FacebookTwitterGoogle+RedditEmail